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See Article, pages 715–724Since its widespread application in the late 90s, adult-
to-adult LDLT has been the focus of many debates in
Western countries. While the number of LDLT proce-
dures peaked in 2001 in Europe and the USA, there
has been, thereafter, a signiﬁcant decrease of cases in
the USA and no further increase in Europe (Fig. 1).
For example, the number of patients undergoing LDLT
dropped from 518 in 2001 to 318 in 2005 and to a pro-
jected ﬁgure of 168 in 2009, representing a 67% decrease,
which currently represents only 3% of all adult liver
transplantations performed in the USA.
The recent history of LDLT at the University of
Pittsburgh has been the subject of considerable external
scrutiny in the public press [1] and professional liver
transplantation community. The manuscript by Marsh
et al. [2] comprehensively describes the outcomes of
right lobe LDLT donors and recipients at Pittsburgh
since 2003, when the volumes of LDLT dramatically
increased with the arrival of a new surgical team. While
there are other single-center, retrospective studies from
mature liver programs reporting complications, most
of which were published 8–10 years ago, this manuscript
is novel in at least three aspects compared to previous
reports. First, it comes from Dr. Thomas E. Starzl,
and every transplant physician would like to know his
opinion on the procedure, because he has been unchar-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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model of end-stage liver disease.acteristically quiet with his written, public expression
regarding LDLT during its expansive application in
the past 20 years. Second, it is the most careful and
timely analysis on this topic currently available and
third it is a call for caution as complications may occur,
even more frequently, after the learning curve is com-
pleted. Therefore, this publication from Pittsburgh, at
this particular time, from this particular author with a
strong statement about the safety and general applica-
tion of LDLT is worthy of careful consideration.
The main message of this study is the high incidence of
complications, particularly severe biliary complications,
in recipients from LDLT, although one year patient/
graft survival was, respectively, 91% and 84%. Those
results for morbidity are somewhat alarming considering
the elective nature of the procedure and the relatively low
MELD scores (MELD < 13 in most recipients) indicat-
ing a low risk of dying on the waiting list. Unexpectedly,
the results even worsened during the last 2 years of the
studied period, highlighting a potential risk for ‘‘relaxed
vigilance once the procedure becomes routine”. While
there was no donor death, a signiﬁcant incidence of
severe negative events was noted in the early postopera-
tive period, mostly occurring in overweight living
donors.
Acknowledging the unique relevance of this study,
there are some criticisms, which must be discussed.
The purpose of the study (as stated in the Introduction)
is to clarify controversies surrounding LDLT simply by
retrospectively reviewing 121 cases at their center over a
4-year period. Such a single-center study is not opti-
mally conﬁgured to make this determination. Other ser-
ies revealed a variety of results with usually lesser rates
of postoperative negative events (Table 1). NoteworthyPublished by Elsevier B.V. All rights reserved.
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Fig. 1. Evolution of the number of living donor liver transplantations.
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ies despite higher risk in recipients (MELD often > 22).
This better outcome is likely related to the use of thin
donors and possibly better donor–recipient match. The
results from a study recently published by the adult-to-
adult living donor liver transplant study group
(A2ALL) indicates a signiﬁcant survival advantage from
the selection of LDLT compared to remaining on the
transplant list [3]. The A2ALL study is the largest anal-
ysis about recipient risk and beneﬁt from the time of
donor evaluation.
On the donor side, the statement in the Methods that
there ‘‘are insurance-driven policies mandating prompt
return of the donor to their primary care provider” is
unusual in other areas in the US or elsewhere. Donors,
can be, should be and, in fact, are seen or contacted at
many centers for post-operative follow-up. We may sus-
pect that in Pittsburgh the absence of such a protocolTable 1
Recipient outcome after right hemi-liver living donor liver transplantation.
Author Period n Survival MELD Biliary
Marsh et al. [2] First half 60 95% (1y) 13 23 (38%
Second half 61 87% (1y) 13 28 (46%
Freise et al. [3] LDLT 6 20 167 #c 15 84 (50%
LDLT > 20 217 77 (36%
Chan et al. [6] Era Ia 50 86% (3y) 29 #c
Era II 184 26
Shah et al. [7] 128 #c 14 41 (32%
Shah et al. [8] 153 91% (1y) 15 #c
Hwang et al. [9] 215 #c #c 48 (21%
Kokudo et al. [10] 114 85% (3y) 17 31 (27%
Icoz et al. [11] 50 78% (1y) #c 15 (30%
Fan et al. [12] 100 #c #c 26 (26%
Marcos et al. [13] Ab 20 80% (?) #c 7 (35%
B 20 95% (?) 0
Testa et al. [14] 30 80% (1y) #c 8 (27%
a LDLT between May 1996 and May 2006, Era I: ﬁrst 50 cases, Era II: re
b A: LDLT between June and December 1998, B: LDLT between January
c Not reported.
* p < 0.05.may likely lead to under-reporting of donor complica-
tions. Thus, the incidence of complications on the donor
side might even be higher.
Despite those criticisms inherent in the study design,
the conclusions drawn by the authors are critically
important. For the ﬁrst time, authors report an increas-
ing incidence of complications in spite of increasing
experience with better outcome (Table 1). This observa-
tion challenges the concept of the learning curve, as their
incidence of complications increased with the number of
cases performed, which is in contrast to every available
report.
While this study does not oﬀer the largest series of
patients treated with this procedure, it is a most objec-
tive assessment of morbidity by the treatment based
ﬁve-tier Clavien system [4,5]. Logically, two questions
arise consequently
 Are the results representative of the ‘‘real” world or
are they more related to institutional problems of a
single center?
 Is the data from other centers misleading because of
less reported morbidity due to diﬀerent and not com-
parable classiﬁcation systems?
While many available studies provided a focus on
donor morbidity, the data in terms of recipient outcome
are mostly incomplete ([6–14], Table 1). Rarely stan-
dardized grading systems are applied and only limited
series report on complication development over time.
In addition, most single centers have yielded a lower
incidence of biliary and vascular complications than
reported here despite the use of higher MELD recipi-
ents. From that point of view, the answer to thecomplications Vascular complications No serious complication
) 6 (10%) 26 (43%)
) 12 (20%)* 15 (25%)
) 21 (13%) #c
)* 15 (7%)
#c #c
) #c #c
#c #c
) #c #c
) 8 (7%) #c
) #c #c
) #c 51 (51%)
) 0 #c
0
) #c #c
maining 184 cases.
and October 1999.
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have a key impact on further policies to oﬀer LDLT.
The authors of this study provide new, objective and
timely information which will be useful to better discuss
LDLT. Of importance, they do not condemn right hemi-
liver living donor liver transplantation, but make a call
for appropriate monitoring of outcome, and a need for
improvement to enable this approach to remain a viable
option in some patients with cancer or end-stage liver
diseases. The fact that complications increased over time
within the same surgical team may serve as an alarming
signal for all programs and help to ensure more accurate
and continuous assessment of morbidity. Because the
conclusions are those of the single most important liver
transplant physician in the world, whose name is synon-
ymous with the procedure, all LDLT physicians would
be well-served by carefully reading the ﬁnale (the last
four paragraphs) of this work as they continue their
work in this important and ever-evolving ﬁeld.References
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